| US 7,465,537 B2 | ||
| Compounds and methods for inhibiting hepatitis C virus replication | ||
| Kevin D. Raney, Little Rock, Ark. (US); Craig E. Cameron, State College, Pa. (US); Bhuvanesh Dave, Little Rock, Ark. (US); Joshua Sakon, Fayetteville, Ark. (US); Jeff Zhiqiang Lu, Towson, Md. (US); Samuel G. Mackintosh, Little Rock, Ark. (US); and Thomas A. Jennings, Little Rock, Ark. (US) | ||
| Assigned to The Board of Trustees of the University of Arkansas, Little Rock, Ark. (US) | ||
| Filed on May 01, 2005, as Appl. No. 11/119,587. | ||
| Prior Publication US 2006/0246421 A1, Nov. 02, 2006 | ||
| Int. Cl. C12Q 1/68 (2006.01); C12N 4/48 (2006.01) | ||
| U.S. Cl. 435—5 [424/149.1; 530/350] | 6 Claims |
| 1. A method of inhibiting hepatitis C virus (HCV) replication in cells infected with HCV comprising:
contacting the cells with an agent that inhibits NS3 enzyme activity by inhibiting NS3 oligomerization; wherein the agent
reduces replication of viral nucleic acid in the cells or spread of virus to other cells;
wherein the agent is a vector expressing a dominant-negative mutant NS3 gene that expresses an ATPase-deficient NS3 protein
that is 90% identical to SEQ ID NO:3 and the step of contacting the agent comprises transforming the cells with the vector;
wherein the ATPase-deficient NS3 protein comprises a D290A mutation; and
wherein the cells are in vitro.
|